Home / Pharma Healthcare / Global Cancer Biomarkers Market Outlook 2018-2023

Global Cancer Biomarkers Market Outlook 2018-2023

  • Id : RNR-54107
  • Category : Pharma Healthcare
  • Publish Date : 2018
  • Pages : 0
  • Format : PDF
License Type

Description
According to Stratistics MRC, the Global Cancer Biomarkers market is estimated at $9215.32 million in 2018 and is expected to reach $20958.63 million by 2023 growing at a CAGR of 12.5% from 2018 to 2023. Technological improvements, huge investment flow for Research and Development and increasing usage in drug development and drug delivery are the factors driving the market growth. On the other hand, Sample collection and storage issue and poor reimbursement policies are hampering the market. Growing awareness for personalized medication is the opportunity for the market growth.

North America captured huge share in terms of revenue owing to raising awareness towards cancer diagnostics. However, Asia Pacific is anticipated to be the fastest growing region with highest CAGR during forecast period, because of increasing demand for non invasive diagnosis in this region. The diagnostics segment holds largest share in the market, followed by drug discovery and development.

Some of the key players in the market include Abbott Laboratories, Becton Dickinson and Company, Correlogic Systems, Inc., Agilent Technologies, Biomerieux S.A., Astellas Pharma US Inc., Roche Diagnostics Corp., Astex Pharmaceuticals, Agendia Bv, Diadexus, Inc., Ambrilia Biopharma, CuraGen, Gen-Probe Inc, Beckman Coulter, Inc., Clarient, Inc, Biocurex Inc., and Aureon Laboratories, Inc.

Services Covered:
• Biomakers validation and testing
• Sample preparation
• Assay development

Diseases Covered:
• Lung Cancer
• Cervical Cancer
• Prostate Cancer
• Colorectal Cancer
• Breast  Cancer
• Other Cancers

Profiling Technologies Covered:
• Omics Technologies
o Transcriptomics
o Proteomics
§ Protein Microarray Technology
§ Peptide Array Technology
§ 2-D Gel Electrophoresis
§ Mass Spectrometry
• Imaging Mass Spectrometry
• Maldi Mass Spectrometry
§ Antibody Array Technology
o Genomics
§ Microarrays
§ Next Generation Sequencing (NGS)
§ PCR (Polymer Chain Reaction)
o Pharmacogenomics
o Metabolomics
• Bioinformatics
• IVD multivariate index assays
• Cytogenetics
o DNA microarrays
o Ish (In Situ Hybridization)
• Immunoassays
o Flow Cytometry
o Elisa
o Immunohistochemistry (IHC)
• Imaging Technologies
o Mammography
o Ultrasound
o Magnetic Resonance Imaging (MRI)
o Computed Tomography (CT)
o Positron Emission Tomography (PET)

Applications Covered:
• Risk Assessment
• Drug Discovery and Development
• Drug formulation
• Diagnostics
• Prognostics
• Other Applications

Types covered:
• Genetic Biomarkers
• Protein Biomarkers
• Other Types
o Carbohydrate biomarkers
o Cell biomarkers
o Viral biomarkers

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain  
o Rest of Europe    
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific    
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements